Navigation Links
Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Date:12/8/2008

ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company will hold an investor conference call to discuss results from its Phase II human clinical trial in healthy adult subjects of Novavax's seasonal influenza VLP vaccine candidate at 11:00 a.m. Eastern Time on December 11, 2008.

The call will be hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management, including Chief Medical Officer, Dr. Penny Heaton. A question and answer session will follow the presentation of the data. The dial-in number for the conference call is USA and Canada (866) 814 8448 International: (703) 639 1367

A live audio and presentation webcast of the conference call will be available at http://www.novavax.com. Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. A replay of the webcast will be available for 90 days after the webcast and a replay of the conference call will also be available by telephone beginning 1pm EST. December 11, 2008 through midnight December 13, 2008. To access the telephone replay, dial (703) 925 2533 and enter pass code 1313471.

About Novavax, Inc.

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statements

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before FDA can be applied for and the FDA may not approve the pandemic vaccine even if further trial results are similar to those disclosed herein; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group ... Ross is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, ... hematopoietic stem cell transplantation for hematologic disorders and the suppression of graft vs. host ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice ... electrical, mechanical and electromechanical patent applications. He has an electrical engineering and computer ...
(Date:4/26/2016)... , ... April 26, 2016 , ... Mr. Palmer created ... RPO, signing the first multi-million dollar, multi-year managed services contract in the U.S. intelligence ... Michael join our leadership team,” said John Younger, founder of Accolo. “We are ...
(Date:4/26/2016)... VIENNA and ... The prize recognizes the innovation capabilities ... innovations that will benefit patients and laboratory diagnostics ... ) , Norma Instruments , ... setting products in the field of hematology, announced ...
Breaking Biology Technology:
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
Breaking Biology News(10 mins):